Paul Chlebeck, MD
Family Medicine · Sioux Falls, SDNPI 1669483632
Payments from drug & device makers
Across 67 payments — averaging $17.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$148
- Novo Nordisk$138
- Lilly USA, LLC$83
- Boehringer Ingelheim$82
- AbbVie$80
- Astellas Pharma US Inc$67
- plus $556 from 24 others
What the payments were for
- Food & beverage$1,154100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 9 | $148 |
| Novo Nordisk | 8 | $138 |
| Lilly USA, LLC | 5 | $83 |
| Boehringer Ingelheim | 5 | $82 |
| AbbVie | 1 | $80 |
| Astellas Pharma US Inc | 4 | $67 |
| Bayer | 3 | $47 |
| AstraZeneca | 3 | $43 |
| Mylan Specialty L.p. | 3 | $43 |
| Supernus Pharmaceuticals, Inc. | 2 | $33 |
| Ultragenyx Pharmaceutical Inc. | 2 | $33 |
| Daiichi Sankyo Inc. | 2 | $33 |
| Merck | 2 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $26 |
| Novartis | 1 | $23 |
| The Binding Site Inc. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $19 |
| Exeltis, USA Inc. | 1 | $18 |
| Vertex | 1 | $16 |
| Abbott | 1 | $16 |
| Nabriva Therapeutics, PLC | 1 | $16 |
| Medtronic | 1 | $16 |
| GSK | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Adlon Therapeutics L.p. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Gilead | 1 | $11 |
How this compares
$1,154 in reported general payments places this provider in the 80th percentile of 408 family medicine providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 59 | $50,694 |
| XareltoRivaroxaban | 44 | $38,840 |
| EliquisApixaban | 27 | $38,669 |
| OzempicSemaglutide | 23 | $31,938 |
| TrulicityDulaglutide | 22 | $24,572 |
| RybelsusSemaglutide | 24 | $21,877 |
| JanuviaSitagliptin Phosphate | 20 | $19,986 |
| LinzessLinaclotide | 31 | $18,633 |
| FarxigaDapagliflozin Propanediol | 19 | $18,484 |
| Bydureon BciseExenatide Microspheres | 16 | $18,327 |
| MounjaroTirzepatide | 11 | $11,267 |
| Victoza 3-PakLiraglutide | 11 | $8,416 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $8,189 |
| Sucralfate | 44 | $7,185 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 26 | $7,002 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr | $82 | $57,69685 claims |
| Novo NordiskOzempic, Rybelsus | $138 | $53,81547 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $83 | $35,83933 claims |
| MerckJanuvia, Belsomra | $29 | $24,68031 claims |
| AbbVieLinzess | $80 | $18,63331 claims |
| AstraZenecaFarxiga | $43 | $18,48419 claims |
| GSKTrelegy Ellipta | $15 | $8,18911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 408 family medicine providers in South Dakota.
Other family medicine in Sioux Falls
- Elizabeth JensenSioux Falls$106K
- Chad ThurySioux Falls$47K
- Andrew BurchettSioux Falls$13K
- Lornell HansenSioux Falls$11K
- Jeffry MeyerSioux Falls$8K
- Scott BoyensSioux Falls$6K
- Jason WurthSioux Falls$4K
- Dustin SnellingSioux Falls$4K
- William BuchnerSioux Falls$3K
- Jennifer SchrieverSioux Falls$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.